Canadian Court Upholds Lipitor Patent

Law360, New York (March 21, 2008, 12:00 AM EDT) -- After a series of unfavorable rulings for Pfizer Inc., a Canadian appeals court has upheld the pharmaceutical giant's patent for Lipitor, delivering a setback to Ranbaxy Laboratories Ltd. in its quest to market a generic version of the blockbuster cholesterol drug.

The Federal Court of Appeal of Canada ruled Thursday that Ranbaxy's lower-priced knockoff would not be entitled to regulatory approval until Pfizer's patent expires in July 2010, according to Pfizer.

“This decision sends a strong signal about the importance of protecting intellectual property in Canada,...
To view the full article, register now.